Cure8 research brief
MMP-2 regulates tissue remodeling and inflammation in IBD; targeting it might help prevent barrier damage, chronic inflammation, or fibrosis but requires selective approaches to avoid harming normal repair processes.
Researchers studying IBD pathogenesis or drug discovery, clinicians interested in emerging pharmacologic targets for IBD, and patients curious about future targeted-therapy directions.
This article is a scholarly review summarizing MMP-2 biology, mechanisms that regulate its activity, and how dysregulation may contribute to epithelial barrier breakdown, immune cell infiltration, chronic inflammation, and fibrotic change in IBD.
The authors evaluate natural and synthetic MMP-2 modulators (including plant polyphenols, peptides, small molecules, and peptidomimetics) and discuss delivery approaches such as nanocarriers intended to increase site-specificity and reduce systemic toxicity.
The review stresses limitations of broad-spectrum MMP inhibition and the need for precision strategies that preserve normal tissue remodeling while reducing pathological activity.
It also highlights emerging tools—single-cell and spatial transcriptomics, organoids, and microbiome-informed models—that may aid development of next-generation MMP-2–targeted therapies.
This item is a narrative/review article (abstract provided). It summarizes preclinical and early-stage therapeutic strategies rather than reporting new clinical trial results. Discussion of potential treatments is conceptual; efficacy and safety in humans remain to be established.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of interest: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Macrophages are central regulators of intestinal inflammation and repair; understanding their diversity and how to modulate them could lead to new, more targeted treatments for Crohn's disease and ulcerative colitis.
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
